Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Preface [Hot topic:Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)] promotion: free to download

Volume:3   Issue:5
Pp: i-i
Paul Workman
DOI: 10.2174/1568009033481840

Order Reprints Order Eprints

Structure and Functional Relationships of Hsp90

Volume:3   Issue:5
Pp: 301-323
Chrisostomos Prodromou and Laurence H. Pearl
DOI: 10.2174/1568009033481877

Order Reprints Order Eprints

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

Volume:3   Issue:5
Pp: 349-358
Luke Whitesell, Rochelle Bagatell and Ryan Falsey
DOI: 10.2174/1568009033481787

Order Reprints Order Eprints

Development of Radicicol Analogues

Volume:3   Issue:5
Pp: 359-369
Shiro Soga, Yukimasa Shiotsu, Shiro Akinaga and Sreenath V. Sharma
DOI: 10.2174/1568009033481859

Order Reprints Order Eprints

Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

Volume:3   Issue:5
Pp: 371-376
Gabriela Chiosis, Brian Lucas, Henri Huezo, David Solit, Andrea Basso and Neal Rosen
DOI: 10.2174/1568009033481778

Order Reprints Order Eprints

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

Volume:3   Issue:5
Pp: 377-383
Edward A. Sausville, Joseph E. Tomaszewski and Percy Ivy
DOI: 10.2174/1568009033481831

Order Reprints Order Eprints